Genocea Biosciences Inc (GNCAQ)

[NY1972]

From IOVA:

Appropriate amount of TIL was manufactured
from tumors regardless of location of resection

Target lesion SOD reductions were seen across
the range of TIL total cell dose

For each 6-month decrease in exposure to prior anti–PD-1 / anti–PD-L1, the median DOR to lifileucel will be nearly doubled.